Editas Medicine (EDIT) vs Kyverna Therapeutics (KYTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Editas Medicine is the larger company by market cap ($422.3 million vs $381.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | KYTX |
|---|---|---|
| Share price | $2.75 | $6.17 |
| Market cap | $422.35M | $381.57M |
| 1-day change | +0.73% | +0.16% |
| YTD return | — | -34.36% |
| 1-year return | — | +14.05% |
| 5-year return | -92.77% | — |
| EPS (TTM) | $-0.68 | $-2.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.54 | $13.67 |
| 52-week low | $1.66 | $5.94 |
| Distance from 52-week high | -39.39% | -54.86% |
| Average volume | 2.48M | 907.11K |
| Shares outstanding | 153.58M | 61.84M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
EDIT vs KYTX FAQ
Which is bigger, Editas Medicine or Kyverna Therapeutics?
Editas Medicine (EDIT) is larger, with a market capitalization of $422.35M compared with $381.57M for Kyverna Therapeutics (KYTX).
Are Editas Medicine and Kyverna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.